Susquehanna restated their neutral rating on shares of Humana Inc. (NYSE:HUM) in a research note published on Sunday. The firm currently has a $200.00 price target on the insurance provider’s stock, up from their prior price target of $180.00.
HUM has been the topic of a number of other reports. Zacks Investment Research lowered shares of Humana from a buy rating to a hold rating in a research report on Wednesday, September 21st. Royal Bank Of Canada lowered their target price on shares of Humana from $222.00 to $217.00 and set a sector perform rating on the stock in a research report on Thursday, October 13th. Barclays PLC restated an equal weight rating and set a $191.00 target price on shares of Humana in a research report on Friday, October 14th. Evercore ISI started coverage on shares of Humana in a research report on Thursday, September 22nd. They set a buy rating and a $200.00 target price on the stock. Finally, Argus restated a hold rating on shares of Humana in a research report on Tuesday, August 23rd. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Humana presently has a consensus rating of Buy and a consensus target price of $208.14.
Humana (NYSE:HUM) traded down 1.44% during trading on Friday, reaching $213.63. 1,219,443 shares of the company’s stock were exchanged. The firm has a market capitalization of $31.85 billion, a price-to-earnings ratio of 28.89 and a beta of 0.89. The stock has a 50-day moving average price of $187.41 and a 200 day moving average price of $178.89. Humana has a 52 week low of $150.00 and a 52 week high of $217.80.
Humana (NYSE:HUM) last announced its earnings results on Friday, November 4th. The insurance provider reported $3.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.09 by $0.09. The business had revenue of $13.69 billion for the quarter, compared to analyst estimates of $13.41 billion. Humana had a net margin of 2.00% and a return on equity of 12.32%. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period last year, the firm posted $2.16 earnings per share. Equities research analysts forecast that Humana will post $9.51 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Mideast Time and is the propert of of Mideast Time. If you are viewing this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this piece can be viewed at http://www.mideasttime.com/susquehanna-reaffirms-neutral-rating-for-humana-inc-hum/1436553.html.
The company also recently announced a quarterly dividend, which will be paid on Friday, January 27th. Investors of record on Thursday, January 12th will be paid a $0.29 dividend. This represents a $1.16 annualized dividend and a yield of 0.54%. The ex-dividend date of this dividend is Tuesday, January 10th. Humana’s payout ratio is 15.96%.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Daiwa SB Investments Ltd. increased its position in shares of Humana by 1.4% in the third quarter. Daiwa SB Investments Ltd. now owns 730 shares of the insurance provider’s stock valued at $129,000 after buying an additional 10 shares during the last quarter. ARGI Investment Services LLC increased its position in shares of Humana by 0.3% in the third quarter. ARGI Investment Services LLC now owns 5,602 shares of the insurance provider’s stock valued at $991,000 after buying an additional 17 shares during the last quarter. Northwestern Mutual Investment Management Company LLC increased its position in shares of Humana by 0.4% in the second quarter. Northwestern Mutual Investment Management Company LLC now owns 5,684 shares of the insurance provider’s stock valued at $1,022,000 after buying an additional 22 shares during the last quarter. Fifth Third Bancorp increased its position in shares of Humana by 0.5% in the second quarter. Fifth Third Bancorp now owns 4,547 shares of the insurance provider’s stock valued at $818,000 after buying an additional 23 shares during the last quarter. Finally, Savant Capital LLC increased its position in shares of Humana by 1.3% in the second quarter. Savant Capital LLC now owns 2,380 shares of the insurance provider’s stock valued at $428,000 after buying an additional 30 shares during the last quarter. 91.71% of the stock is owned by hedge funds and other institutional investors.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, marketed to individuals or directly via group accounts, as well as individual commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.